|
End-of-day quote
London S.E.
|
||
| - GBX | - |
|
| 10-02 | Major drugmakers turn to China for licensing deals | RE |
| 10-01 | GSK plc : JP Morgan reiterates its Sell rating | ZD |
| Market Cap | 71.3B 94.34B 83.82B 78.23B 134B 9,069B 136B 947B 367B 4,636B 354B 347B 14,879B | P/E 2026 * |
13.8x | P/E 2027 * | 11.4x |
|---|---|---|---|---|---|
| Enterprise Value | 92.54B 122B 109B 102B 175B 11,770B 176B 1,229B 476B 6,017B 460B 450B 19,310B | EV / Sales 2026 * |
2.73x | EV / Sales 2027 * | 2.53x |
| Free-Float |
92.75% | Yield 2026 * |
3.9% | Yield 2027 * | 4.2% |
Last Transcript: GlaxoSmithKline plc
| Manager | Title | Age | Since |
|---|---|---|---|
Luke Miels
CEO | Chief Executive Officer | 52 | 01/01/2026 |
Julie Brown
DFI | Director of Finance/CFO | 64 | 01/05/2023 |
James Ford
CMP | Compliance Officer | - | 01/08/2018 |
| Director | Title | Age | Since |
|---|---|---|---|
Luke Miels
BRD | Director/Board Member | 52 | 06/05/2026 |
Hal Barron
BRD | Director/Board Member | 64 | 01/01/2018 |
Jonathan Symonds
CHM | Chairman | 67 | 01/09/2019 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +0.10% | -3.33% | +35.54% | +111.52% | 1,019B | |
| -0.98% | -6.63% | +34.94% | +61.58% | 617B | |
| -0.33% | -1.72% | +13.69% | +77.49% | 464B | |
| -3.43% | -5.96% | +57.46% | +34.97% | 356B | |
| +0.48% | -2.42% | +20.25% | +40.58% | 333B | |
| -0.13% | -4.25% | +9.87% | +33.26% | 267B | |
| -1.03% | -5.78% | -7.51% | +7.96% | 244B | |
| -0.92% | -4.38% | +35.94% | +50.83% | 218B | |
| -0.67% | -5.84% | +26.18% | +91.85% | 179B | |
| Average | -0.76% | -3.54% | +25.15% | +56.67% | 410.8B | |
| Weighted average by Cap. | -0.62% | -3.54% | +28.31% | +68.14% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 33.91B 44.87B 39.86B 37.21B 63.96B 4,313B 64.56B 450B 174B 2,205B 168B 165B 7,077B | 35.49B 46.95B 41.71B 38.93B 66.93B 4,513B 67.55B 471B 183B 2,307B 176B 172B 7,405B |
| Net income | 5.19B 6.86B 6.1B 5.69B 9.78B 660B 9.88B 68.88B 26.69B 337B 25.77B 25.21B 1,083B | 6.2B 8.21B 7.29B 6.81B 11.7B 789B 11.81B 82.38B 31.92B 403B 30.82B 30.15B 1,295B |
| Net Debt | 21.24B 28.1B 24.96B 23.3B 40.05B 2,701B 40.42B 282B 109B 1,381B 105B 103B 4,431B | 18.53B 24.51B 21.78B 20.33B 34.94B 2,356B 35.27B 246B 95.32B 1,205B 92.03B 90.03B 3,866B |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Select your edition
All financial news and data tailored to specific country editions
